mm-asct-eligibility

name

mm-asct-eligibility

description

Decide whether a newly-diagnosed multiple myeloma (NDMM) patient is eligible for high-dose melphalan + autologous stem cell transplantation (ASCT) as part of front-line therapy, using the EHA-ESMO 2021 criteria. Trigger when a clinician asks "is this myeloma patient fit for transplant", "ASCT eligibility for myeloma", "transplant-eligible NDMM", "should I refer for stem cell transplant", "high-dose melphalan candidate", or any decision about whether a newly-diagnosed myeloma patient should go to upfront ASCT.

Multiple Myeloma — ASCT Eligibility (Front-Line)

Use this skill when a patient with newly diagnosed multiple myeloma (NDMM) has just been diagnosed, before selecting an induction regimen — because eligibility for ASCT changes the front-line plan.

---

STEP 1 — Apply the primary eligibility filter

Eligible for HDT + ASCT if ALL of the following are true:

1. Age <70 years (chronological).
2. No significant comorbidities that would preclude high-dose melphalan or stem cell mobilisation.
3. Adequate organ function (cardiac, pulmonary, hepatic, renal — assess case-by-case).
4. Performance status consistent with tolerating intensive therapy.

If all four are met → eligible for ASCT. Go to Step 3. If any one fails → likely ineligible. Go to Step 2.

---

STEP 2 — Borderline cases (age 70–75 or single comorbidity)

The age cut-off is not absolute. A fit 72-year-old with no comorbidities may still benefit from ASCT, while a 65-year-old with severe COPD may not. Consider:

• Biological vs. chronological age — frailty score, IMWG frailty index, or geriatric assessment.
• Renal impairment alone is NOT a contraindication — ASCT is feasible in dialysis-dependent patients with melphalan dose reduction (140 mg/m²).
• Cardiac comorbidity (EF <40%, severe valvular disease) is a more rigid contraindication than renal disease.
• Patient preference matters — discuss the PFS benefit (~14-month gain in mPFS) vs. transplant-related morbidity.

If still unclear → refer for transplant assessment rather than rule out unilaterally.

---

STEP 3 — Front-line plan for ASCT-ELIGIBLE patients

Recommended sequence:

1. Induction (4–6 cycles)
   • First option: DaraVTD [I, A] — new standard of care
   • Alternative: VRd [II, B] — best risk-benefit among triplets but not EMA-approved for this indication
   • If first option not available: VTD [I, A] or VCD [II, B]
2. Stem cell mobilisation + harvest
3. Conditioning: HDM 200 mg/m² [I, A] (reduce to 140 mg/m² for severe renal impairment)
4. ASCT
5. Consolidation (optional)
   • 2 cycles of VRd if VCD was used for induction [II, B]
   • Tandem ASCT for high-risk cytogenetics (del17p, t(4;14), t(14;16), 1q gain) or after VCD induction [II, B]
6. Maintenance: lenalidomide until progression [I, A]
   • Bortezomib may be considered for high-risk disease [II, B]

---

STEP 4 — Front-line plan for ASCT-INELIGIBLE patients

If ineligible, switch to a transplant-ineligible regimen. Three new standards of care:

• DaraRd [I, A] — until progression
• DaraVMP [I, A] — 9 cycles VMP + Dara, then Dara until progression
• VRd [I, A] — preferred if Dara-based regimen not available

Less-preferred alternatives if none of the above are accessible:

• VMP [I, A]
• Rd [I, A]

For frail elderly patients (≥75y or frailty index intermediate/high), apply dose reductions per IMWG frailty consensus.

---

CLINICAL GUARDRAILS

• Don't rule out ASCT on age alone if the patient is fit — transplant centres routinely accept patients up to 75. The "<70" cut-off is a guideline default, not a hard ceiling.
• Renal failure / dialysis is NOT a contraindication to ASCT — use HDM 140 mg/m².
• Cardiac dysfunction (EF <40%) and severe pulmonary disease are the most rigid hard stops.
• Allo-SCT post-ASCT is NOT recommended for high-risk disease — tandem ASCT gives equivalent or better OS with lower TRM (10-year data).
• Decide on induction regimen knowing the ASCT plan — DaraVTD, VTD, VCD, and VRd are designed to preserve stem cell yield. Avoid prolonged lenalidomide pre-harvest if ASCT is planned (>4 cycles can compromise mobilisation).
• Don't delay the eligibility decision — induction regimen choice depends on it. Make the call at the time of diagnosis, not after 3 cycles.

---

SOURCE

Dimopoulos MA, Moreau P, Terpos E, et al. Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology 2021;32(3):309–322. DOI: 10.1016/j.annonc.2020.11.014

Adapted from the front-line therapy section and Figure 1.